This case demonstrates the feasibility of using a biological mitral valve prosthesis in a young woman to allow for future pregnancies without lifelong anticoagulation, and the successful use of transcatheter valve-in-valve technology to treat subsequent structural valve deterioration 18 years later.
Answers are grounded in this paper and cite their sources.
Supports feasibility of pregnancy after bioprosthetic MVR; leaves open optimal valve choice and durability in reproductive-age women.
As a clinical case, we present the "portrait" of a woman patient with acquired mitral valve (MV) defect against the background of infective endocarditis which was diagnosed during the third trimester of pregnancy. The patient underwent mitral valve replacement surgery with biological prosthesis "KemKor" followed by two successful deliveries. In 18 years after the correction of the mitral valve defect, she developed valve prosthesis dysfunction therefore, she underwent endovascular transcatheter implantation of bioprosthesis by method "prosthesis-into-prosthesis" in the mitral position. This clinical case is unique in terms of the reasoning the biological prosthesis choice to correct acquired MV defect in a patient of reproductive age, the long-term period of the bioprosthesis functioning and the correction of further developed valve dysfunction using the techniques of transcatheter implantation.
No takes yet. Share an insight, caveat, or question.
Dren’ et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: